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Abstract: The autonomic nervous system interacts in the pathophysiology of heart failure. Dysfunction of the sympa-
thetic nervous system has been identified as an important prognostic marker in patients with chronic heart failure. At pre-
sent, cardiac sympathetic nerve imaging with 123-iodine metaiodobenzylguanidine [123-I MIBG] has been employed 
most frequently for the assessment of cardiac sympathetic innervation and activation pattern. The majority of studies have 
shown that cardiac sympathetic dysfunction as assessed with 123-I MIBG imaging is a powerful predictor for heart failure 
mortality and morbidity. Additionally, 123-I MIBG imaging can be used for prediction of potentially lethal ventricular 
tachyarrhythmias in heart failure patients. At present however, the lack of standardization of 123-I MIBG imaging proce-
dures represents an evident issue. Standardized criteria on the use of 123-I MIBG imaging will further strengthen the 
clinical use of 123-I MIBG imaging in heart failure patients. 
Keywords: Cardiac 123-iodine metaiodobenzylguanidine imaging, heart failure, heart-to-mediastinum ratio, myocardial sym-
pathetic innervation, prognosis, ventricular arrhythmia. 
CARDIAC AUTONOMIC NERVOUS SYSTEM IN 
HEART FAILURE 
  Chronic heart failure represents one of the most impor-
tant challenges in clinical cardiology since several decades 
[1, 2]. The American Heart Association has recently updated 
their report on the heart disease and stroke statistics and in-
dicated that approximately 5.3 millions patients are diag-
nosed with heart failure in the United States [2]. Addition-
ally, heart failure was identified as the primary mode of 
death in 284,365 patients in the United States in 2004 [2]. 
Moreover, heart failure represents an important health care 
problem as the annual hospital admissions for heart failure 
increased considerably from approximately 400,000 in 1979 
to more than 1,084,000 in 2005. As a result, an exponential 
increase has been observed in the direct and indirect costs 
involved in the diagnosis and treatment of heart failure, ex-
ceeding $34 billion in 2008 [2].  
  Heart failure is a pathophysiologic condition character-
ized by a reduced myocardial pump function which lacks the 
ability to supply peripheral tissues with sufficient metabolic 
requirements. Different pathophysiologic mechanisms have 
been related to the development and propagation of the clini-
cal syndrome of heart failure, as shown in Table 1. In case of 
a reduced cardiac function, several compensation pathways 
become activated that aim to preserve cardiovascular homeo-
stasis. One of the these mechanisms that plays an essential 
role in patients with heart failure is the neurohormonalsys-
tem, consisting of the adrenergic nervous system and the 
renin-angiotensin-aldosteron system  [RAAS] [3, 4]. In   
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patients with heart failure, a decreased cardiac output results 
in an activation of the high-pressure baroreceptors of the left 
ventricle [LV], carotid sinus and aortic arch [4]. Activated 
baroreceptors generate afferent stimuli to cardio-regulatory 
centers of the central nervous system which leads to an acti-
vation of sympathetic nervous pathways. Additionally, a 
diminished effective renal blood flow  [caused by a reduced 
pump function] activates the RAAS system via the release of 
renin from the juxtaglomerular apparatus. Renin catalyzes 
the conversion of angiotensinogen  [produced in the liver] 
into the inactive angiotensin I. Subsequently, angiotensin I is 
metabolized into angiotensin II by the angiotensin convert-
ing enzyme, predominantly within the vascular bed of the 
lungs. Angiotensin II is involved in sodium- and water reten-
tion as well as vascular constriction. Furthermore, angio-
tensin II can lead to activation of other compensatory 
mechanisms in heart failure, including the sympathetic nerv-
ous system. Moreover, a reduced cardiac stroke volume re-
sults in an increased [LV] end-diastolic volume along with a 
rise in LV end-diastolic pressure. Based upon the Frank-
Starling principle, these increased preload conditions will 
enhance the force of myocardial contraction, which compen-
sates the decline in cardiac stroke volume. 
  In the early phase of heart failure, the hemodynamic con-
sequences of a deteriorated cardiac pump function are com-
pensated by the neurohormonal feedback mechanisms [3, 4]. 
However, in patients with chronic heart failure, the neuro-
hormonal feedback mechanisms are detrimental as they may 
cause cardiac hypertrophy and fibrosis, leading to cardiovas-
cular remodeling and restructuring. Additionally, myocardial 
 -adrenoceptors may have become desensitized and down-
regulated in a chronic state of heart failure, leading to a pro-
gressive decline in cardiac function [3].  36    Current Cardiology Reviews, 2011, Vol. 7, No. 1  Fan et al. 
Table 1. Overview of Common Causes of Chronic Heart Fail-
ure 
1. Myocardial  disorder 
  Coronary artery disease 
 Hypertrophic  cardiomyopathy 
  Hypo / hyperthyroidism 
 Neurohormonal  excess 
 Inflammatory  or  immune 
  Metabolic disorder or infiltrative 
 Toxic 
 Idiopathic  cardiomyopathy 
2. Hemodynamic  overload 
 Hypertension 
 Renal  failure 
3. Cardiac  arrhythmia 
  Atrial / ventricular arrhythmias 
  Sinus node dysfunction 
 Atrioventricular  conduction  block 
4.  Cardiac valve disease 
  Mitral valve stenosis or regurgitation 
  Aortic valve stenosis or regurgitation 
5. Pericardial  disease 
 Constrictive 
6. Extra-cardiac  pathology 
 Anemia 
 Sepsis 
 Iatrogenic 
7. Congenital  heart  disease 
  Congenitally corrected transposition of great arteries 
  Univentricular heart or double inlet left ventricle 
 Tetralogy  of  Fallot 
 Pulmonary  atresia 
  Ventricular and atrial septal defect 
  Accordingly, the sympathetic nervous system plays an 
essential role in the pathophysiology of the clinical syn-
drome of heart failure [3, 4]. Sympathetic stimuli are con-
ducted  via adrenergic fibers, located predominantly in the 
superficial subepicardium following the major epicardial 
coronary arteries [5]. In patients with a failing heart, the ac-
tivated sympathetic nervous system can modulate heart rate  
[chronotropic effect], atrioventricular conductance  [dromo-
tropic effect] as well as the contractile force  [inotropic ef-
fect]. The noradrenergic function of the sympathetic nervous 
system is primarily mediated by the uptake and release of the 
neurotransmitter norepinephrine, which binds to adrenocep-
tors located on the specific target cells. Different mecha-
nisms have been identified that modulate the uptake of nore-
pinephrine from the presynaptic cleft, including the uptake-1  
[neuronal] and uptake-2  [non-neuronal] mechanisms. The 
neuronal uptake  [uptake-1] of norepinephrine is performed 
by the norepinephrine transporter  [NET] protein located at 
the plasma membrane of the terminal dilated regions of the 
sympathetic neurone, whereas the extra-neuronal uptake   
[uptake-2] is predominantly performed via the postsynaptic 
sodium-dependent, low-affinity transport mechanism. Cur-
rently, these pre- and postsynaptic uptake mechanisms have 
been used frequently to depict the sympathetic innervation 
and activation pattern in patients with chronic heart failure 
[3, 4, 6-7]. 
SYMPATHETIC NERVE IMAGING 
  To date, positron emission tomography  [PET] and single 
photon emission computed tomography  [SPECT] are the 
only two imaging modalities that permit visualization of 
sympathetic innervation and activation [6-7]. Moreover, both 
noninvasive imaging techniques allow assessment of global 
and regional abnormalities in myocardial sympathetic inner-
vation. One of the major advantages of PET imaging remains 
the fact that it allows absolute quantification of abnormalities 
in sympathetic innervation with a superior spatial and tempo-
ral resolution as compared to SPECT imaging [7]. Addition-
ally, it is important to note that the majority of PET tracers is 
more closely related to the endogenous neurotransmitters 
when compared to the tracers used for SPECT imaging. At 
present, hydroxyephedrine labeled with carbon-11  [11C-
HED] represents the most commonly used PET tracer for 
sympathetic nerve imaging. The frequent use of 11C-HED 
for sympathetic nerve imaging may be explained by the fact 
that 11C-HED shows a high affinity for the NET protein   
[uptake-1] located on the sympathetic neurone, and impor-
tantly, 11C-HED is not metabolized by catechol-O-methyl 
transferase  [COMT] or monoamine oxidase  [MAO] en-
zymes in the terminal endings of the sympathetic neurone. 
Thus far, different studies have sought to quantify global and 
regional abnormalities in sympathetic innervation in patients 
with heart failure using PET imaging [8-10]. Vesalainen et
al. [8] performed an interesting study that evaluated myocar-
dial retention of 11C-HED in patients with and without heart 
failure. The patient population consisted of 30 patients with 
mild to moderate heart failure, as reflected by New York 
Heart Association  [NYHA] functional class II/III, and 7 
healthy control patients. Global cardiac retention index of 
11C-HED was assessed in all patients using resting PET 
imaging. The study has shown that global 11C-HED reten-
tion index was significantly lower in patient with heart fail-
ure as compared to the healthy control patients  [0.29 ± 0.10 
vs. 0.42 ± 0.07, p<0.01]. In addition, Pietilä et al. [9] evalu-
ated the prognostic value of global cardiac 11C-HED reten-
tion in 46 patients with NYHA class II/III heart failure. Dur-
ing follow-up, cardiac mortality and heart transplantations 
were documented. The study has demonstrated that patients 
with heart failure showed significantly lower 11C-HED re-
tention index when compared to patients without heart fail-
ure  [0.18 ± 0.06 vs. 0.28 ± 0.04, p<0.01] (Fig. 1). Moreover, 
Cox proportional hazards regression analysis showed that 
11C-HED retention was significantly associated with cardiac 
mortality or the occurrence of heart transplantation   
[p=0.014]. Additionally, regional abnormalities in sympa-
thetic nerve innervation have been assessed with PET imag-
ing and 11C-HED, as shown in Fig. (2) [9, 10]. Hartmann  Cardiac Sympathetic Nerve Imaging in Heart Failure  Current Cardiology Reviews, 2011, Vol. 7, No. 1    37
Fig. (1). Cardiac sympathetic innervation can be assessed with posi-
tron emission tomography [PET] imaging with carbon-11 hy-
droxyephedrine [11C-HED]. Patients with heart failure showed 
significantly lower retention of 11C-HED when compared to pa-
tients without heart failure [0.18 ± 0.06 vs. 0.28 ± 0.04, p<0.01]. 
Data are based on reference 9. 
and colleagues [10] have evaluated sympathetic innervation 
pattern in patients with dilated cardiomyopathy and moder-
ate-to-severe heart failure. In total, 29 heart failure patients 
and 8 healthy control patients underwent dynamic PET im-
aging to assess regional abnormalities in 11C-HED retention 
using the 9-segment model, placed over the polar map. 
Tracer activity was expressed per cardiac segment as an ab-
solute or relative  [percentage of the maximal tracer activity] 
percentage. Patients with heart failure showed a significantly 
lower retention of 11C-HED than patients without heart fail-
ure  [6.2 (1.6) %/min vs. 10.7 (1.0) %/min, p<0.01]. Impor-
tantly, as compared to the healthy controls, considerable re-
duction in 11C-HED retention was observed in the apical   
[p<0.01] and inferoapical  [p<0.05] segments in patients with 
dilated cardiomyopathy and heart failure. Despite the poten-
tials of PET imaging, several factors have been acknowl-
edged that hamper its large-scale clinical use, including the 
complex production and delivery of short-live PET tracers, 
extensive processing requirements and limited availability of 
PET cameras. Furthermore, its widespread use has been re-
stricted by the fact that PET imaging is a costly imaging 
technique  [the production of PET tracers as well as PET 
equipment are expensive] when compared to other non-
invasive imaging techniques [7]. 
  Currently, 123-iodine metaiodobenzylguanidine  [123-I 
MIBG] represents the most commonly used radiopharmaceu-
tical agent for evaluation of the sympathetic innervation pat-
tern in patients with heart failure, originating from ischemic 
or non-ischemic cause [11-15]. MIBG is a false neurotrans-
mitter that uses the same uptake and storage mechanisms as 
the endogenously produced neurotransmitter norepinephrine. 
Different mechanisms have been identified that facilitate the 
uptake of MIBG from the synaptic cleft, including the up-
take-1  [neuronal] and uptake-2  [non-neuronal] mechanisms. 
In human hearts, the neuronal uptake of MIBG plays the 
most important role, since MIBG uptake was absent in 
Fig. (2). Positron emission tomography [PET] imaging with hy-
droxyephedrine labeled with carbon-11 [11C-HED] allows assess-
ment of cardiac sympathetic innervation. Moreover, PET imaging 
with 11C-HED can be used for assessment of regional abnormali-
ties in cardiac sympathetic innervation in patients with heart failure, 
originating from either dilated [panel A] or ischemic [panel B] car-
diomyopathy. Reprinted with permission from reference 9. 
denervated myocardium of patients with previous cardiac 
transplantation [16]. Importantly, MIBG represents an inter-
esting and potent radiopharmaceutical agent for sympathetic 
nerve imaging as it has been shown to provide strong signal 
intensity due to the fact that MIBG is accumulated in storage 
vesicles of the sympathetic neurone, without further meta-
bolic degradation. The signals are used for planar and 
SPECT imaging which are usually performed at two differ-
ent intervals; early planar and SPECT images are acquired 
15 minutes after tracer administration, whereas delayed pla-
nar and SPECT images are acquired 4 hours after tracer ad-
ministration, as illustrated in Fig. (3)  [17]. From planar im-
ages, semi-quantitative measurements of 123-I MIBG uptake 
can be derived that provide information on global innerva-
tion pattern, as shown in Fig. (4). Currently, the most com-
monly used semi-quantitative parameter of 123-I MIBG up-
take is the heart-to-mediastinum  [H/M] ratio which is calcu-
lated by dividing the mean counts per pixel within the car-
diac region of interest by the mean counts per pixel within 
the upper mediastinum. In addition, 123-I MIBG SPECT 
imaging provides information on regional sympathetic in-
nervation of the myocardium (Fig. 5). 
PROGNOSTIC VALUE OF 123-I MIBG IMAGING IN 
PATIENTS WITH HEART FAILURE 
  Over the recent decades, a large number of studies have 
sought to determine the prognostic value of sympathetic 
nerve imaging with 123-I MIBG in patients diagnosed with 
chronic heart failure [11-15, 18]. The 123-I MIBG studies 
have shown that patients with heart failure show a reduced 
myocardial uptake of 123-I MIBG, and more importantly, 
these 123-I MIBG studies have indicated that heart failure 
patients with the lowest myocardial 123-I MIBG uptake tend 
to have the worst prognosis [11-15, 18]. In this perspective, 
an interesting study was performed by Merlet et al. [13] who 
sought to determine whether 123-I MIBG imaging could 
predict clinical outcome in patients with heart failure. In to-
tal, 112 patients with idiopathic dilated cardiomyopathy and 
NYHA II-IV heart failure underwent sympathetic nerve im-
aging with 123-I MIBG. Additionally, patients underwent 38 Current Cardiology Reviews, 2011, Vol. 7, No. 1  Fan et al. 
Fig. (5). Regional abnormalities in cardiac sympathetic innervation 
can be assessed with 123-iodine metaiodobenzylguanidine [123-I 
MIBG] single photon emission computed tomography [SPECT] 
imaging. This is an example of a patient with a marked defect in the 
sympathetic innervation of the inferior wall. 
M-mode echocardiography, chest X-ray, right-sided heart 
catheterization, and exercise testing to identify potential pre-
dictors for clinical outcome. Furthermore, the plasma nore-
pinephrine concentration was determined in all patients. 
Over a mean follow-up of 27 ± 20 months, cardiac mortality 
was documented in 27 patients and cardiac transplantation in 
19 patients. Multivariate stepwise regression analysis re-
vealed that MIBG uptake  [p<0.01] and circulating norepi-
nephrine  [p<0.01] were independently associated with car-
diac mortality during follow-up. Furthermore, Cohen-Solal 
et al. [18] evaluated the hypothesis that reduced sympathetic 
innervation, as assessed with 123-I MIBG imaging, was as-
sociated with poor outcome in heart failure patients. The 
prospective analysis was based on 93 patients with chronic 
heart failure  [either due to ischemic or dilated cardiomyopa-
thy] and depressed LV systolic function  [LV ejection frac-
tion  [LVEF] <45%]. Late H/M ratio  [p=0.04] and oxygen 
consumption  [VO2]  [p<0.01] were significantly associated 
with all-cause mortality or the occurrence of cardiac trans-
plantation. Importantly, patients with a late H/M ratio <1.27 
showed a significantly lower survival rate as compared to 
patients with a late H/M ratio >1.27  [p<0.01]. 
  Beyond myocardial 123-I MIBG uptake, planar imaging 
can also be used to assess the myocardial washout rate in 
patients with heart failure [19-22]. Myocardial washout rate 
has been recognized as an indicator of the sympathetic car-
diac tone, as it reflects the degree in which MIBG is washed 
out of the myocardium over time. So far, a large number of 
Fig. (3). Schematic illustration of the cardiac 123-iodine metaiodobenzylguanidine [123-I MIBG] imaging protocol. First, thyroid blockade
is usually performed with oral administration of potassium perchlorate or iodine at least 30 minutes prior to 123-I MIBG acquisition. Once 
123-I MIBG has been administered, cardiac images are acquired according to a two-step protocol consisting of planar and single photon 
emission computed tomography [SPECT] imaging performed at 15 minutes [early imaging] and 4 hours [late imaging]. 
Fig. (4). Global sympathetic innervation can be assessed from planar imaging with 123-iodine metaiodobenzylguanidine [123-I MIBG]. The 
heart-to-mediastinum [H/M] ratio is calculated by dividing the mean counts per pixel within the cardiac region of interest by the mean counts 
per pixel within the upper mediastinum. A. Example of a patient with heart failure and reduced global uptake of 123-I MIBG within the 
myocardium. The late H/M ratio was 1.31. B. Example of a patient with heart failure and normal global uptake of 123-I MIBG within the 
myocardium. The H/M ratio was 1.80 on delayed planar imaging. Cardiac Sympathetic Nerve Imaging in Heart Failure  Current Cardiology Reviews, 2011, Vol. 7, No. 1    39
studies have evaluated the predictive value of myocardial 
washout rate, and have shown that heart failure patients with 
an increased cardiac washout rate are at risk for adverse car-
diovascular events [19-21]. An important study was per-
formed by Ogita et al. [20] who evaluated whether sympa-
thetic nerve imaging with 123-I MIBG was able to predict 
clinical outcome in 79 patients with chronic heart failure. 
The patient population was divided into patients with a low  
[<27%] or high  [>27%] myocardial washout rate. The cutoff 
value was derived from the mean value of the myocardial 
washout rate from the patient population. In total, 23   
[29.1%] patients showed an adverse cardiac event over a 
mean follow-up of 31 months. Additionally, morbidity   
[p<0.01] and mortality  [p<0.01] rates were significantly 
higher in patients with increased cardiac washout rate as 
compared to patients without an increased cardiac washout 
rate. Another important study was performed by Yamada et
al. [21] who compared the prognostic value of 123-I MIBG 
parameters with heart rate variability  [HRV] in 65 patients 
with mild-to-moderate heart failure and reduced LV systolic 
function  [LVEF <40%]. Patients were followed-up from 
study enrollment to cardiac death or first documented hospi-
talization for worsening heart failure. Multivariate Cox pro-
portional hazards regression analysis showed that myocardial 
washout rate was independently associated with the occur-
rence of cardiac death or hospitalization  [HR 1.072, 95% CI 
1.01-1.14, p=0.029]. Accordingly, these studies have shown 
that myocardial uptake  [H/M ratio] and washout  [washout 
rate] of 123-I MIBG can be used for prediction of outcome 
in patients with heart failure. 
  In addition to single-center studies, Agostini et al. [14] 
performed a retrospective multicenter study evaluating the 
predictive value of 123-I MIBG variables derived from pre-
viously acquired 123-I MIBG images. More specifically, the 
multicenter study was designed to evaluate whether a stan-
dardized quantitative approach yielded similar results when 
compared to the previously reported findings from single-
center studies. In total, 290 patients with NYHA functional 
class II-IV heart failure and depressed LV systolic function  
[LVEF <50%] were enrolled. All 123-I MIBG scans were 
analyzed in one core laboratory by three experienced and 
independent observers. The delayed H/M ratios were ob-
tained from planar imaging using a standardized approach. 
The late H/M ratios were related to the occurrence of major 
cardiovascular events during follow-up, including docu-
mented cardiac death, heart transplantation and potentially 
lethal ventricular arrhythmia. The study has shown that pa-
tients with major cardiovascular events showed significantly 
lower late H/M ratio as compared to patients without adverse 
cardiovascular events  [1.51 ± 0.30 vs. 1.97 ± 0.54, p<0.01] 
(Fig. 6). Additionally, multivariate analysis revealed that late 
H/M ratio and LVEF were independently associated with the 
occurrence of adverse events. Accordingly, the study has 
shown that late H/M ratio could be used for identification of 
heart failure patients at risk for adverse events. Importantly, 
the study has demonstrated that the use of a standard quanti-
tative approach yielded similar results when compared to 
previously findings from single-center studies, regardless of 
differences in imaging protocols and technical equipment. 
Fig. (6). Differences in heart-to-mediastinum [H/M] ratio in pa-
tients with and without adverse events. Delayed H/M ratio was 
significantly lower in heart failure patients with adverse events 
when compared to patients without adverse events during follow-up 
[1.51 ± 0.30 vs. 1.97 ± 0.54, p<0.01]. Data based on reference 14. 
123-I MIBG IMAGING FOR IDENTIFICATION OF 
PATIENTS AT RISK FOR VENTRICULAR AR-
RHYTHMIAS 
  Abnormalities of the autonomic nervous system, as as-
sessed with 123-I MIBG imaging, is also thought to interact 
in the pathophysiology of ventricular tachyarrhythmias [23, 
24]. It has been postulated that viable myocardium with de-
prived sympathetic innervation may show an exaggerated 
and hypersensitive response to circulating catecholamines. 
More specifically, an increased automaticity and enhanced 
triggering may be observed in denervated viable myocar-
dium [23]. Pilot studies have related reduced myocardial 
uptake of 123-I MIBG with the occurrence of ventricular 
arrhythmias [25, 26]. Arora et al. [27] performed a pilot stu-
dy evaluating the hypothesis that sympathetic nerve imaging 
with 123-I MIBG could be used for prediction of appropriate 
implantable cardioverter-defibrillator  [ICD] therapy. Ap-
propriate ICD therapy  [defined as the first documented ICD 
therapy in response to ventricular tachycardia or ventricular 
fibrillation] was used as a surrogate for potentially lethal 
ventricular tachyarrhythmias. For comparison reasons, the 
patient population was divided into patients with  [n=10] or 
without  [n=7] appropriate ICD therapy during follow-up. 
Patients with appropriate ICD therapy showed significantly 
reduced global and regional 123-I MIBG uptake as com-
pared to patients without appropriate ICD therapy during 
follow-up  [p<0.05]. The authors have postulated that 123-I 
MIBG imaging can be used for the identification of patients 
at risk for potentially lethal ventricular tachyarrhythmias. 
Another important study was performed by Tamaki et al.
[22] who evaluated whether 123-I MIBG imaging could be 
valuable for prediction of sudden arrhythmic death in 106 
consecutive patients diagnosed with chronic heart failure. 
The primary study endpoint was defined as the occurrence of 
sudden arrhythmic death, whereas secondary endpoints were 
defined as cardiac death or death due to progressive heart  40    Current Cardiology Reviews, 2011, Vol. 7, No. 1  Fan et al. 
failure. In total, 38  [36%] patients died over a mean follow-
up of 65 ± 31 months, including 18  [17%] patients who died 
because of sudden cardiac death. In multivariate analysis, 
myocardial washout rate  [HR 1.052, 95% CI 1.020-1.085, 
p<0.01] and LVEF  [HR 0.930, 95% CI 0.870-0.995, 
p=0.0341] were independently associated with sudden ar-
rhythmic death. Importantly, both parameters were signifi-
cant predictors for cardiac death or death due to progressive 
heart failure. 
  The value of 123-I MIBG SPECT imaging for prediction 
of ventricular arrhythmias has also been demonstrated in 
several studies [26, 28]. Recently, Bax et al. [26] evaluated 
whether 123-I MIBG imaging was associated with inducibil-
ity of ventricular arrhythmias during electrophysiologic test-
ing. In total, 50 patients underwent electrophysiologic test-
ing, 123-I MIBG and technetium-99m tetrofosmin imaging. 
Among all variables, only the summed defect score on de-
layed 123-I MIBG SPECT imaging was significantly differ-
ent between patients with or without a positive electrophysi-
ologic test. Patients with a positive electrophysiologic test 
showed significantly larger 123-I MIBG SPECT defects as 
compared to patients without a positive electrophysiologic 
test  [42.7 ± 8.8 vs. 34.9 ± 9.8, p<0.05]. Furthermore, the 
hypothesis that 123-I MIBG imaging may be useful for pre-
diction of potentially lethal ventricular arrhythmias was re-
cently evaluated in 116 patients currently indicated for ICD 
therapy [28]. Before ICD implantation, all patients under-
went myocardial perfusion imaging to assess myocardial 
infarction and perfusion abnormalities. Additionally, patients 
underwent sympathetic nerve imaging with 123-I MIBG 
prior to ICD implantation. During follow-up, appropriate 
ICD therapy  [used as a surrogate of potentially lethal ven-
tricular tachyarrhythmias] and cardiac mortality were docu-
mented. In this study, the primary endpoint was defined as 
the first documented appropriate ICD therapy, whereas the 
composite of appropriate ICD therapy and cardiac death was 
defined as the secondary endpoint. Over a mean follow-up of 
23 ± 15 months, appropriate ICD therapy was reported in 24  
[21%] patients and cardiac death in 13  [11%] patients. Im-
portantly, 123-I MIBG SPECT defect score on delayed im-
aging was an independent predictor for both endpoints. 
Moreover, patients with extensive sympathetic denervation  
[defined as summed late 123-I MIBG SPECT defect score 
>26] showed significantly more appropriate ICD therapy   
[52% vs. 5%, p<0.01] when compared to patients with lim-
ited sympathetic denervation  [summed late 123-I MIBG 
SPECT defect score 26] at 3-year follow-up. Accordingly, 
123-I MIBG planar and SPECT imaging can be used for the 
identification of patients at risk for potentially lethal ven-
tricular tachyarrhythmias. 
IMPLEMENTATION OF 123-I MIBG IMAGING INTO 
CLINICAL PRACTICE 
  Accordingly, abnormalities in cardiac sympathetic inner-
vation or activation play an important role in prognostication 
of patients with heart failure. A detailed evaluation of ab-
normalities in cardiac sympathetic nervous system can be 
performed by cardiac 123-I MIBG imaging. Cardiac 123-I 
MIBG images can be acquired safely in nearly all patients 
with heart failure, except in patients with known hypersensi-
tivity for MIBG compounds or MIBG sulphate. Despite the 
potentials of 123-I MIBG imaging, some impeding factors 
have been recognized that hamper the clinical implementa-
tion of sympathetic nerve imaging with 123-I MIBG [29]. 
One of the important factors that has been identified is the 
lack of standardization and validation of cardiac 123-I MIBG 
imaging and post-processing procedures [29, 30]. At present, 
123-I MIBG studies have shown considerable heterogeneity 
in the use of technical equipment, imaging protocols and 
quantitative post-processing analysis [11-13, 15, 29]. A large 
number of studies has used low-energy parallel-hole collima-
tors for 123-I MIBG image acquisition, whereas some stud-
ies have used medium-energy parallel-hole collimators [31-
35]. It has been demonstrated that the type of collimator used 
for 123-I MIBG imaging plays an evident role in the assess-
ment of H/M ratios; scatter artifacts due to penetration of the 
collimator septa by high-energy photons are less prominent 
with the use of medium-energy collimators when compared 
to low-energy collimators [34-36]. Moreover, studies have 
demonstrated that the use of medium-energy collimators   
[with thicker septa] results in superior accuracy of semi-
quantitative assessment of myocardial 123-I MIBG uptake 
[34-36]. Additionally, the semi-quantitative assessment of 
myocardial 123-I MIBG uptake and washout can be calcu-
lated using different approaches. In the study by Cohen-Solal 
et al. [18], who sought to determine the prognostic value of 
cardiac 123-I MIBG imaging in 93 heart failure patients, the 
myocardial washout rate was calculated using the following 
formula:  [(H early – H delayed) X 100] / H early. In con-
trast, the myocardial washout rate was calculated with an-
other approach in the study by Ogita et al. [20]; the myocar-
dial washout rate was calculated by the following equation:  
[(H early – M early) – (H late – M late)] / (H early – M 
early). Additionally, differences in myocardial 123-I MIBG 
uptake and washout rate can be related to the fact that some 
studies did not correct for isotope decay [20]. Accordingly, 
improved standardization of 123-I MIBG imaging and post-
processing procedures is currently indicated. Recently, Flo-
tats et al. [17] have published a proposal for standardization 
of 123-I MIBG imaging, including a detailed description of 
patient preparation, data acquisition and post-processing of 
123-I MIBG images. Development of such standardizations 
on the use of 123-I MIBG imaging may further strengthen 
the clinical value of sympathetic nerve imaging with 123-I 
MIBG in patients with heart failure. 
POTENTIAL TECHNICAL PITFALLS OF 123-I MIBG 
IMAGING 
  Although cardiac 123-I MIBG imaging can be used for 
risk stratification of patients with heart failure, some poten-
tial pitfalls of cardiac 123-I MIBG imaging should be ad-
dressed. First, the evaluation of 123-I MIBG SPECT images 
may be hampered by severely reduced myocardial uptake of 
123-I MIBG in patients with advanced heart failure. Fur-
thermore, the readers should be aware of the fact that 123-I 
MIBG shows a reduced uptake in the inferior wall under 
normal conditions [37]. Particularly, elderly patients may 
show reduced uptake of 123-I MIBG in the inferior wall. 
Additionally,  123-I MIBG is also taken up by peripheral 
tissues that are supplied by sympathetic nerves, including the 
liver, lungs and thyroid gland [17]. Moreover, 123-I MIBG 
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patients. In patients with excessive extra-cardiac 123-I 
MIBG uptake, evaluation of 123-I MIBG SPECT images   
[particularly evaluation of the inferior wall] may be difficult. 
In patients with non-diagnostic 123-I MIBG scans, plasma 
norepinephrine levels or the rate of norepinephrine spillover 
can be used for evaluation of sympathetic activation. 
CONCLUSION 
  The autonomic nervous system plays an essential role in 
the pathophysiology of heart failure. Dysfunction of the 
sympathetic nervous system represents an important prog-
nostic marker in patients with chronic heart failure. Most 
commonly, 123-I MIBG imaging has been used for the as-
sessment of abnormalities in cardiac sympathetic innervation 
and activation. Cardiac sympathetic denervation as assessed 
with 123-I MIBG represents an important predictor for heart 
failure mortality and morbidity. Furthermore, 123-I MIBG 
imaging can be used for prediction of potentially lethal ven-
tricular tachyarrhythmias in patients with heart failure. At 
present however, improved standardization of 123-I MIBG 
imaging procedures is indicated. Standardized criteria on the 
use of 123-I MIBG imaging may further strengthen the clini-
cal value of 123-I MIBG imaging in heart failure patients. 
ABBREVIATIONS 
11C-HED =  Carbon-11  hydroxyephedrine  labeled 
ICD =  Implantable  cardioverter-defibrillator 
123-I MIBG  =  123-iodine metaiodobenzylguanidine 
LV  =  Left ventricle / left ventricular 
LVEF  =  Left ventricular ejection fraction 
NET =  Norepinephrine  transporter 
NYHA  =  New York Heart Association 
PET  =  Positron emission tomography  
RAAS  =  Renin angiotensin aldosteron system 
SPECT  =  Single photon emission computed tomo-
graphy 
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